Chronic Inflammation in Asthma: Looking Beyond the Th2 Cell.

Area of Science:

• Immunology
• Respiratory Medicine
• Cell Biology

Background:

• Asthma is a common airway inflammatory disease, with severe, therapy-resistant cases posing significant challenges.
• Type 2 immunity, mediated by CD4+ T helper 2 (Th2) cells producing cytokines like IL-4, IL-5, IL-9, and IL-13, is central to most asthma.
• Severe asthma mechanisms are poorly understood, especially in patients unresponsive to corticosteroids.

Purpose of the Study:

• To review the pathophysiology of asthma, focusing on severe and therapy-resistant forms.
• To highlight the roles of less-studied immune cells, including group 2 innate lymphoid cells (ILC2s) and type 2 CD8+ cytotoxic T (Tc2) cells.
• To discuss the involvement of non-type 2 immunity in severe asthma pathogenesis.

Main Methods:

• Review of current scientific literature on asthma pathophysiology.
• Analysis of the roles of various lymphocyte subsets in airway inflammation.
• Emphasis on mechanisms contributing to severe and corticosteroid-resistant asthma.

Main Results:

• ILC2s and Tc2 cells, alongside Th2 cells, contribute to type 2 inflammation in asthma.
• These alternative cell types may be more prevalent and corticosteroid-resistant in severe asthma.
• Non-type 2 immune responses are implicated in severe asthma lacking typical type 2 inflammation.

Conclusions:

• Understanding the diverse immune players in severe asthma is crucial for developing new therapies.
• ILC2s, Tc2 cells, and non-type 2 immunity represent important targets for treating therapy-resistant asthma.
• Further research into these alternative pathways may unlock effective treatments for severe asthma patients.